BNCT for head and neck malignancies
- Conditions
- Advanced or recurrent head and neck malignanciesHead and neck malignancies, BNCT
- Registration Number
- JPRN-jRCTs061180067
- Lead Sponsor
- Kamitani Nobuhiko
- Brief Summary
The findings in our clinical trials indicate that BNCT is effective against a recurrent cancer after conventional therapies, if BPA accumulates sufficiently in the tumor.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 21
1) With recurrence head and neck melanoma that surgical treatment is not indicated.
2) The depth of tumor, less than 6cm, and without distant metastases.
3) T/N ratio is more than 2.5 using 18F-BPA-PET.
4) KPS>= 60 percentage
5) Serum creatinine<=1.2mg/dl(male), 1.0mg/dl(female)
1) Double cancer with disease-free period less than 3 years
2) Distant metastases
3) Active infection
4) Adverse events mere than Grade 3 induced by previous therapy
5) Tumor exposure to the skin and tumor invasion to the carotid artery
6) Severe heart complications
7) Difficulty of patient fixation for irradiation
8) White blood cell<=3000/mm3, Platelet<=100,000/mm3
9) Unsuitable patients for medical or social situation
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Tumor response in 6 months after BNCT
- Secondary Outcome Measures
Name Time Method Adverse events in 6 months after BNCT